MLYS - Company ID 0001933414
The table below shows Mineralys Therapeutics, Inc.'s income statement line items across its last 4 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of revenue | - | - | - | - |
| Gross profit | - | - | - | - |
| R&D | $132.01M | $168.58M | $70.36M | $26.25M |
| SG&A | $38.59M | $23.82M | $14.30M | $5.23M |
| Operating income | -$170.60M | -$192.40M | -$84.66M | -$31.48M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Income tax | $0.00 | - | - | - |
| Net income | -$154.65M | -$177.81M | -$71.90M | -$29.80M |
| EPS (diluted) | -$2.29 | -$3.66 | -$1.99 | -$5.77 |